Targeted therapies in metastatic castration-resistant prostate cancer: Beyond the androgen receptor - Abstract

Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death in Western countries.

Most patients with prostate cancer respond to initial androgen deprivation therapy but eventually progress to castration-resistant prostate cancer (CRPC). Although androgen receptor signaling remains the main driver in CRPC, a growing body of evidence suggests that other pathways are involved in this progression. This article reviews the preclinical data and current status of clinical trials therapeutically targeting tubulin, DNA repair, molecular chaperones such as CLU and Hsp27, tyrosine kinases, and DNA repair.

Written by:
Loriot Y, Zoubeidi A, Gleave ME.   Are you the author?
Vancouver Prostate Centre, University of British Columbia, 899 12th Avenue West, Vancouver, British Columbia V5Z 1M9, Canada.

Reference: Urol Clin North Am. 2012 Nov;39(4):517-31.
doi: 10.1016/j.ucl.2012.07.008

PubMed Abstract
PMID: 23084528 Prostate Cancer Section